Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines for serious diseases with significant unmet medical need, with a focus on oncology. Founded in 2019 and headquartered in Millbrae, California, the company completed its initial public offering on the Nasdaq in 2026.

Eikon combines biology, engineering and computational methods, including super-resolution microscopy that tracks the movement of individual proteins in living cells, to support drug discovery. Its pipeline includes a systemic TLR7/8 dual agonist designed to stimulate immune responses against tumors, selective PARP1 inhibitors for several cancers including a brain-penetrant candidate aimed at brain tumors and metastases, a WRN helicase inhibitor for MSI-high tumors, and a next-generation androgen receptor antagonist intended for prostate cancer.

The company's shares trade under the ticker EIKN.